SCHEMBL3637342

SCHEMBL3637342

CC(C)(C)OC(=O)N1CCC(C(C#N)c2ccc3c(c2)OCO3)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.52
BMP1 P13497 1/20 0.47
MGLL Q99685 2/20 0.47
SCD5 Q86SK9 1/20 0.47
MAPT P10636 8/20 0.46
POLB P06746 2/20 0.46
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
GPR183 P32249 1/20 0.45
TP53 P04637 2/20 0.44
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EDNRA P25101 1/20 0.43
FAAH O00519 1/20 0.43
DPP4 P27487 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20198176 0.86 MGLL (0.61) MMP13BMP1MGLLSCD5MAPT
SCHEMBL13984629 0.85 MGLL (0.46) MMP13MGLLLMNANPC1ALDH1A1
SCHEMBL3637345 0.84 MGLL (0.48) MGLLMAPTPOLBLMNANPC1
SCHEMBL23211814 0.81 MMP13 (0.52) MMP13MAPTPOLBNPC1ALDH1A1
SCHEMBL21381612 0.81 MMP13 (0.52) MMP13MAPTPOLBNPC1ALDH1A1
SCHEMBL16657606 0.81 CNR1 (0.52) MGLLMAPTLMNANPC1ALDH1A1
SCHEMBL23587587 0.80 GPR119 (0.54) MMP13MGLLMAPTNPC1ALDH1A1
SCHEMBL4236045 0.79 MMP13 (0.51) MMP13MAPTNPC1ALDH1A1MAPK1
SCHEMBL2843865 0.79 ACHE (0.51) MGLLLMNAALDH1A1L3MBTL1FAAH
SCHEMBL27008546 0.78 HPGD (0.67) MMP13SCD5MAPTPOLBKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R MMP13 2382/4885BMP1 1704/4885MGLL 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.